Cargando…
CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells
Understanding the mechanism of chemoresistance and disease progression in patients with prostate cancer is important for developing novel treatment strategies. In particular, developing resistance to cabazitaxel is a major challenge in patients with docetaxel‐resistant and castration‐resistant prost...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317938/ https://www.ncbi.nlm.nih.gov/pubmed/30426599 http://dx.doi.org/10.1111/cas.13876 |
_version_ | 1783384802062237696 |
---|---|
author | Natsagdorj, Ariunbold Izumi, Kouji Hiratsuka, Kaoru Machioka, Kazuaki Iwamoto, Hiroaki Naito, Renato Makino, Tomoyuki Kadomoto, Suguru Shigehara, Kazuyoshi Kadono, Yoshifumi Lin, Wen‐Jye Maolake, Aerken Mizokami, Atsushi |
author_facet | Natsagdorj, Ariunbold Izumi, Kouji Hiratsuka, Kaoru Machioka, Kazuaki Iwamoto, Hiroaki Naito, Renato Makino, Tomoyuki Kadomoto, Suguru Shigehara, Kazuyoshi Kadono, Yoshifumi Lin, Wen‐Jye Maolake, Aerken Mizokami, Atsushi |
author_sort | Natsagdorj, Ariunbold |
collection | PubMed |
description | Understanding the mechanism of chemoresistance and disease progression in patients with prostate cancer is important for developing novel treatment strategies. In particular, developing resistance to cabazitaxel is a major challenge in patients with docetaxel‐resistant and castration‐resistant prostate cancer (CRPC) because cabazitaxel is often administered as a last resort. However, the mechanism by which cabazitaxel resistance develops is still unclear. C‐C motif chemokine ligands (CCL) were shown to contribute to the castration resistance of prostate cancer cells via an autocrine mechanism. Therefore, we focused on CCL as key factors of chemoresistance in prostate cancer cells. We previously established a cabazitaxel‐resistant cell line, DU145‐TxR/CxR, from a previously established paclitaxel‐resistant cell line, DU145‐TxR. cDNA microarray analysis revealed that the expression of CCL2 was upregulated in both DU145‐TxR and DU145‐TxR/CxR cells compared with DU145 cells. The secreted CCL2 protein level in DU145‐TxR and DU145‐TxR/CxR cells was also higher than in parental DU145 cells. The stimulation of DU145 cells with CCL2 increased the proliferation rate under treatments with cabazitaxel, and a CCR2 (a specific receptor of CCL2) antagonist suppressed the proliferation of DU145‐TxR and DU145‐TxR/CxR cells under treatments of cabazitaxel. The CCL2‐CCR2 axis decreased apoptosis through the inhibition of caspase‐3 and poly(ADP‐ribose) polymerase (PARP). CCL2 is apparently a key contributor to cabazitaxel resistance in prostate cancer cells. Inhibition of the CCL2‐CCR2 axis may be a potential therapeutic strategy against chemoresistant CRPC in combination with cabazitaxel. |
format | Online Article Text |
id | pubmed-6317938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63179382019-01-08 CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells Natsagdorj, Ariunbold Izumi, Kouji Hiratsuka, Kaoru Machioka, Kazuaki Iwamoto, Hiroaki Naito, Renato Makino, Tomoyuki Kadomoto, Suguru Shigehara, Kazuyoshi Kadono, Yoshifumi Lin, Wen‐Jye Maolake, Aerken Mizokami, Atsushi Cancer Sci Original Articles Understanding the mechanism of chemoresistance and disease progression in patients with prostate cancer is important for developing novel treatment strategies. In particular, developing resistance to cabazitaxel is a major challenge in patients with docetaxel‐resistant and castration‐resistant prostate cancer (CRPC) because cabazitaxel is often administered as a last resort. However, the mechanism by which cabazitaxel resistance develops is still unclear. C‐C motif chemokine ligands (CCL) were shown to contribute to the castration resistance of prostate cancer cells via an autocrine mechanism. Therefore, we focused on CCL as key factors of chemoresistance in prostate cancer cells. We previously established a cabazitaxel‐resistant cell line, DU145‐TxR/CxR, from a previously established paclitaxel‐resistant cell line, DU145‐TxR. cDNA microarray analysis revealed that the expression of CCL2 was upregulated in both DU145‐TxR and DU145‐TxR/CxR cells compared with DU145 cells. The secreted CCL2 protein level in DU145‐TxR and DU145‐TxR/CxR cells was also higher than in parental DU145 cells. The stimulation of DU145 cells with CCL2 increased the proliferation rate under treatments with cabazitaxel, and a CCR2 (a specific receptor of CCL2) antagonist suppressed the proliferation of DU145‐TxR and DU145‐TxR/CxR cells under treatments of cabazitaxel. The CCL2‐CCR2 axis decreased apoptosis through the inhibition of caspase‐3 and poly(ADP‐ribose) polymerase (PARP). CCL2 is apparently a key contributor to cabazitaxel resistance in prostate cancer cells. Inhibition of the CCL2‐CCR2 axis may be a potential therapeutic strategy against chemoresistant CRPC in combination with cabazitaxel. John Wiley and Sons Inc. 2018-12-07 2019-01 /pmc/articles/PMC6317938/ /pubmed/30426599 http://dx.doi.org/10.1111/cas.13876 Text en © 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Natsagdorj, Ariunbold Izumi, Kouji Hiratsuka, Kaoru Machioka, Kazuaki Iwamoto, Hiroaki Naito, Renato Makino, Tomoyuki Kadomoto, Suguru Shigehara, Kazuyoshi Kadono, Yoshifumi Lin, Wen‐Jye Maolake, Aerken Mizokami, Atsushi CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells |
title | CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells |
title_full | CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells |
title_fullStr | CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells |
title_full_unstemmed | CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells |
title_short | CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells |
title_sort | ccl2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317938/ https://www.ncbi.nlm.nih.gov/pubmed/30426599 http://dx.doi.org/10.1111/cas.13876 |
work_keys_str_mv | AT natsagdorjariunbold ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT izumikouji ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT hiratsukakaoru ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT machiokakazuaki ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT iwamotohiroaki ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT naitorenato ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT makinotomoyuki ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT kadomotosuguru ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT shigeharakazuyoshi ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT kadonoyoshifumi ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT linwenjye ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT maolakeaerken ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells AT mizokamiatsushi ccl2inducesresistancetotheantiproliferativeeffectofcabazitaxelinprostatecancercells |